Biopharmaceutical industry is constantly looking to shorten product development cycle time and costs. The covid-19 pandemic provided unique set of conditions for the industry to push the boundaries in rapid product development and commercialization. In response to the pandemic, AstraZeneca is
developing a long-acting antibody combination being evaluated for prophylaxis/ treatment of Covid19. The program was highly accelerated to deliver batches manufactured at commercial scale in less than 6 months after program initiation. The presenter served as Operations technical lead, helped
establish commercial manufacturing supply chains, and provided oversight of large-scale drug substance manufacturing for this program. Perspectives on supporting an agile and flexible team to deliver their best under pressure, lessons learnt, and opportunities to leverage learnings for accelerated biologics product development in the future will be presented.
developing a long-acting antibody combination being evaluated for prophylaxis/ treatment of Covid19. The program was highly accelerated to deliver batches manufactured at commercial scale in less than 6 months after program initiation. The presenter served as Operations technical lead, helped
establish commercial manufacturing supply chains, and provided oversight of large-scale drug substance manufacturing for this program. Perspectives on supporting an agile and flexible team to deliver their best under pressure, lessons learnt, and opportunities to leverage learnings for accelerated biologics product development in the future will be presented.
Presenter(s)
Once the content has been viewed and you have attested to it, you will be able to download and print a certificate for PDH credits.
If you have already viewed this content,
please click here
to login.